Stevanato Group S.p.A. (STVN)

Market Cap	6.50B
Revenue (ttm)	1.34B
Net Income (ttm)	158.02M
Shares Out	272.99M
EPS (ttm)	0.57
PE Ratio	41.76
Forward PE	35.95
Dividend	$0.06 (0.26%)
Ex-Dividend Date	Jun 5, 2025

Volume	64,355
Open	24.22
Previous Close	24.20
Day's Range	23.76 - 24.32
52-Week Range	17.12 - 28.00
Beta	0.55
Analysts	Buy
Price Target	25.70 (+7.87%)
Earnings Date	Aug 5, 2025

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,521
• Stock Exchange: NYSE
• Ticker Symbol: STVN
• Website: https://www.stevanatogroup.com

Financial Performance

In 2024, Stevanato Group's revenue was 1.10 billion, an increase of 1.72% compared to the previous year's 1.09 billion. Earnings were 117.78 million, a decrease of -19.13%.

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for STVN stock is "Buy." The 12-month stock price target is $25.7, which is an increase of 7.87% from the latest price.

Price Target

$25.7

(7.87% upside)

Analyst Consensus: Buy